BRPI0819971A2 - anticorpos contra vírus influenza e métodos de seu uso - Google Patents

anticorpos contra vírus influenza e métodos de seu uso

Info

Publication number
BRPI0819971A2
BRPI0819971A2 BRPI0819971A BRPI0819971A BRPI0819971A2 BR PI0819971 A2 BRPI0819971 A2 BR PI0819971A2 BR PI0819971 A BRPI0819971 A BR PI0819971A BR PI0819971 A BRPI0819971 A BR PI0819971A BR PI0819971 A2 BRPI0819971 A2 BR PI0819971A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
influenza viruses
influenza
viruses
Prior art date
Application number
BRPI0819971A
Other languages
English (en)
Inventor
Sui Jianhua
C Liddington Robert
A Marasco Wayne
Original Assignee
Burnham Institute For Medical Res
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Institute For Medical Res, Dana Farber Cancer Inst Inc filed Critical Burnham Institute For Medical Res
Publication of BRPI0819971A2 publication Critical patent/BRPI0819971A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
BRPI0819971A 2007-12-06 2008-12-08 anticorpos contra vírus influenza e métodos de seu uso BRPI0819971A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US572507P 2007-12-06 2007-12-06
US9159908P 2008-08-25 2008-08-25
PCT/US2008/085876 WO2009079259A2 (en) 2007-12-06 2008-12-08 Antibodies against influenza virus and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0819971A2 true BRPI0819971A2 (pt) 2017-06-27

Family

ID=40796093

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819971A BRPI0819971A2 (pt) 2007-12-06 2008-12-08 anticorpos contra vírus influenza e métodos de seu uso

Country Status (18)

Country Link
US (3) US20110038935A1 (pt)
EP (3) EP3333187B1 (pt)
JP (5) JP6149213B2 (pt)
KR (1) KR20100115346A (pt)
CN (1) CN101970483A (pt)
AU (1) AU2008338691B2 (pt)
BR (1) BRPI0819971A2 (pt)
CA (1) CA2708221C (pt)
CO (1) CO6331300A2 (pt)
CR (1) CR11553A (pt)
EC (1) ECSP10010322A (pt)
IL (1) IL206156A0 (pt)
MA (1) MA31991B1 (pt)
MX (1) MX2010006148A (pt)
NZ (1) NZ586611A (pt)
RU (1) RU2010127156A (pt)
WO (1) WO2009079259A2 (pt)
ZA (1) ZA201004478B (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
EP3333187B1 (en) * 2007-12-06 2022-06-22 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
EP2274334A2 (en) 2008-03-28 2011-01-19 Sea Lane Biotechnologies,llc. Neutralizing molecules to viral antigens
WO2010027818A2 (en) * 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
JP5396111B2 (ja) * 2009-03-12 2014-01-22 学校法人慶應義塾 インフルエンザ治療／予防薬
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
BRPI1012749B1 (pt) 2009-05-11 2022-01-11 Janssen Vaccines & Prevention B.V. Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica
AU2010249046A1 (en) 2009-05-13 2011-12-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
JP6210685B2 (ja) * 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
MX342716B (es) 2010-02-18 2016-10-11 Sinai School Medicine Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
EP2545074A4 (en) * 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
EP3900740A1 (en) 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
EP2582721B1 (en) * 2010-06-17 2018-08-22 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
EP2600884A2 (en) * 2010-08-03 2013-06-12 University Of Washington Through Its Center For Comercialization Polypeptides for treating and/or limiting influenza infection
WO2012021786A2 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
MX2013009357A (es) * 2011-02-14 2014-02-17 Theraclone Sciences Inc Composiciones y metodos para la terapia y diagnostico de la influenza.
RU2491338C2 (ru) * 2011-06-30 2013-08-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский Институт гриппа" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "НИИ гриппа" Минздравсоцразвития России) Применение моноклональных антител для идентификации ямагатской или викторианской эволюционных линий вируса гриппа типа в, штамм гибридомы 4н7 для получения моноклональных антител, предназначенных для определения вирусов гриппа в ямагатской ветви, штамм гибридомы в/4н1 для получения моноклональных антител, предназначенных для определения вирусов гриппа в викторианской ветви
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
US9512202B2 (en) 2011-08-27 2016-12-06 University Of Zurich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
CN116162175A (zh) 2011-09-20 2023-05-26 西奈山伊坎医学院 流感病毒疫苗及其应用
DK2793945T3 (en) 2011-12-05 2018-09-03 Trellis Bioscience Llc USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION
EP2793940B1 (en) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SG10201807059QA (en) * 2012-05-10 2018-09-27 Massachusetts Inst Technology Agents for influenza neutralization
CN103592436A (zh) * 2012-08-15 2014-02-19 华中农业大学 一种甲型h1亚型流感病毒抗体阻断elisa试剂盒及应用
CN103665153B (zh) * 2012-09-14 2016-03-16 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1e1
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
MX2015012397A (es) * 2013-03-14 2016-07-26 Contrafect Corp Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada.
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
WO2015020913A2 (en) 2013-08-03 2015-02-12 Marshall Christopher Patrick Influenza hemagglutinin proteins and methods of thereof
US10011649B2 (en) 2013-08-26 2018-07-03 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
EP3070167A4 (en) * 2013-11-06 2017-06-07 Osaka University Antibody having broad neutralizing activity in group 1 influenza a virus
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CA2938726A1 (en) 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CA2940196C (en) 2014-03-19 2023-03-07 Wayne Marasco Immunogenetic restriction on elicitation of antibodies
JP6525214B2 (ja) * 2014-06-03 2019-06-05 国立研究開発法人農業・食品産業技術総合研究機構 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用
CN105301249A (zh) * 2014-07-24 2016-02-03 江苏维赛科技生物发展有限公司 金刚烷胺药物残留快速检测试纸条
CN105301248A (zh) * 2014-07-24 2016-02-03 江苏维赛科技生物发展有限公司 金刚烷胺快速时间分辨荧光免疫层析定量检测试纸条
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
US11505599B2 (en) 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
JP2019515955A (ja) 2016-04-25 2019-06-13 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｓｔａｔ３を結合する抗体医薬
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
CN106146657B (zh) * 2016-07-12 2020-07-17 晋明(天津)生物医药技术开发有限公司 广谱结合流感病毒a的重组抗体片段及其制备方法与应用
CN110214152A (zh) 2016-10-14 2019-09-06 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
US11250327B2 (en) 2016-10-26 2022-02-15 Cognizant Technology Solutions U.S. Corporation Evolution of deep neural network structures
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SI3589730T1 (sl) 2017-02-28 2024-04-30 The Trustees Of The University Of Pennsylvania Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
AU2018229293A1 (en) 2017-02-28 2019-08-29 Janssen Biotech, Inc. Influenza vaccines based on AAV vectors
US11507844B2 (en) 2017-03-07 2022-11-22 Cognizant Technology Solutions U.S. Corporation Asynchronous evaluation strategy for evolution of deep neural networks
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN111065400A (zh) * 2017-10-03 2020-04-24 公益财团法人东京都医学总合研究所 抗流感药物
US11250314B2 (en) 2017-10-27 2022-02-15 Cognizant Technology Solutions U.S. Corporation Beyond shared hierarchies: deep multitask learning through soft layer ordering
US11182677B2 (en) 2017-12-13 2021-11-23 Cognizant Technology Solutions U.S. Corporation Evolving recurrent networks using genetic programming
EP3724819A4 (en) 2017-12-13 2022-06-22 Cognizant Technology Solutions U.S. Corporation SCALABLE ARCHITECTURES FOR THE EVOLUTION OF DEEP NEURAL NETWORKS
MA51681A (fr) 2018-01-26 2021-05-05 Regeneron Pharma Anticorps humains contre l'hémagglutinine de la grippe
US11527308B2 (en) 2018-02-06 2022-12-13 Cognizant Technology Solutions U.S. Corporation Enhanced optimization with composite objectives and novelty-diversity selection
WO2019157257A1 (en) 2018-02-08 2019-08-15 Cognizant Technology Solutions U.S. Corporation System and method for pseudo-task augmentation in deep multitask learning
CN108409841B (zh) * 2018-04-10 2021-06-04 北京康亿鸿科技发展有限公司 用于检测特异性过敏原IgE的单域结合蛋白及应用
KR102143274B1 (ko) 2018-07-19 2020-08-10 전주대학교 산학협력단 이온화 및 나노화 미네랄을 함유하는 고병원성 조류독감 바이러스 소독제 조성물의 제조방법
CN109448781B (zh) * 2018-11-06 2021-09-14 云南大学 一种流感病毒抗原变化的预测方法
CN109608552A (zh) * 2018-12-26 2019-04-12 杭州亿米诺生物科技有限公司 一种小反刍兽疫重组融合蛋白及其制备方法和应用
CN111423507B (zh) * 2019-01-10 2022-04-15 中国科学院分子细胞科学卓越创新中心 广谱性中和流感病毒的全人抗体
US11481639B2 (en) 2019-02-26 2022-10-25 Cognizant Technology Solutions U.S. Corporation Enhanced optimization with composite objectives and novelty pulsation
CA3129731A1 (en) 2019-03-13 2020-09-17 Elliot Meyerson System and method for implementing modular universal reparameterization for deep multi-task learning across diverse domains
WO2020198329A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
US11783195B2 (en) 2019-03-27 2023-10-10 Cognizant Technology Solutions U.S. Corporation Process and system including an optimization engine with evolutionary surrogate-assisted prescriptions
US12026624B2 (en) 2019-05-23 2024-07-02 Cognizant Technology Solutions U.S. Corporation System and method for loss function metalearning for faster, more accurate training, and smaller datasets
EP3996740A4 (en) * 2019-07-12 2023-07-05 Contrafect Corporation THERAPEUTIC PROTEIN FORMULATIONS INCLUDING ANTIBODIES AND THEIR USES
CN115551885A (zh) * 2019-12-11 2022-12-30 威特拉公司 用于治疗和预防流感的组合物和方法
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US12099934B2 (en) * 2020-04-07 2024-09-24 Cognizant Technology Solutions U.S. Corporation Framework for interactive exploration, evaluation, and improvement of AI-generated solutions
US11775841B2 (en) 2020-06-15 2023-10-03 Cognizant Technology Solutions U.S. Corporation Process and system including explainable prescriptions through surrogate-assisted evolution
CN114181303B (zh) * 2020-09-14 2022-12-23 东莞市朋志生物科技有限公司 抗甲型流感病毒的抗体和试剂盒
WO2023201306A1 (en) * 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CN114957479B (zh) * 2022-05-28 2024-06-18 浙江大学医学院附属第一医院 抗H1N1流感病毒双特异性中和抗体Bis-Hu11-1及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP0666923A1 (en) 1991-09-05 1995-08-16 The University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
AU668374B2 (en) 1991-12-10 1996-05-02 Dana-Farber Cancer Institute Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3061960B2 (ja) * 1992-09-17 2000-07-10 寳酒造株式会社 抗ヒトインフルエンザウイルス抗体
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997014809A2 (en) 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1015616A2 (en) 1997-09-19 2000-07-05 Dana Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
WO1999045959A1 (en) 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CA2366054A1 (en) 1999-03-16 2000-09-21 Wayne A. Marasco Lentiviral vector system for high quantity screening
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
AU2002351239A1 (en) 2001-12-04 2003-06-17 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2005005615A2 (en) 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
CN1914226B (zh) * 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
WO2005123774A2 (en) 2004-06-15 2005-12-29 Erol Fikrig Antibodies to west nile virus polypeptides
US8828727B2 (en) 2004-07-21 2014-09-09 Dana-Farber Cancer Institute Lentiviral vectors and uses thereof
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
JP2008528668A (ja) * 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
KR20060089390A (ko) * 2005-02-04 2006-08-09 주식회사 중앙백신연구소 돼지 인플루엔자 바이러스ａ／ｓｗｉｎｅ／ｋｏｒｅａ／ｓ10/2004(ｈ1ｎ1) 및 이의백신
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
AU2006232920B2 (en) * 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP2007000141A (ja) * 2005-05-25 2007-01-11 Tokyo Univ Of Science 完全ヒト抗体産生ハイブリドーマの作製方法、及び融合ミエローマ細胞
WO2007044695A2 (en) 2005-10-07 2007-04-19 Dana-Farber Cancer Institute ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
EP1979379B1 (en) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
WO2009059032A2 (en) 2007-10-30 2009-05-07 University Of Louisville Research Foundation, Inc. Uses and isolation of very small embryonic-like (vsel) stem cells
KR20080090532A (ko) * 2006-01-26 2008-10-08 에이치엑스 디아그노스틱스, 인크. 조류 인플루엔자 바이러스 서브타입 ｈ５ 헤마글루티닌에 결합하는 모노클로날 항체 및 그의 용도
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
EP2489728A1 (en) 2006-06-15 2012-08-22 Neostem, Inc Processing procedure for peripheral blood stem cells
EP2450377A1 (en) * 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
EP3333187B1 (en) 2007-12-06 2022-06-22 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US9340603B2 (en) 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
BRPI1012749B1 (pt) 2009-05-11 2022-01-11 Janssen Vaccines & Prevention B.V. Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
AU2008338691B2 (en) 2015-01-22
WO2009079259A9 (en) 2009-10-01
MA31991B1 (fr) 2011-01-03
JP2017122087A (ja) 2017-07-13
EP3333187B1 (en) 2022-06-22
WO2009079259A2 (en) 2009-06-25
MX2010006148A (es) 2011-02-23
JP2019104736A (ja) 2019-06-27
RU2010127156A (ru) 2012-01-20
CN101970483A (zh) 2011-02-09
CA2708221C (en) 2017-07-25
CA2708221A1 (en) 2009-06-25
EP2222701B1 (en) 2017-11-01
AU2008338691A1 (en) 2009-06-25
EP3524619A1 (en) 2019-08-14
US20110038935A1 (en) 2011-02-17
EP3333187A1 (en) 2018-06-13
JP2015180619A (ja) 2015-10-15
ECSP10010322A (es) 2010-09-30
KR20100115346A (ko) 2010-10-27
EP2222701A2 (en) 2010-09-01
CR11553A (es) 2010-11-12
JP2011506344A (ja) 2011-03-03
IL206156A0 (en) 2010-12-30
JP6149213B2 (ja) 2017-06-21
WO2009079259A3 (en) 2010-02-18
US20140011982A1 (en) 2014-01-09
US20180312575A1 (en) 2018-11-01
CO6331300A2 (es) 2011-10-20
JP2021176841A (ja) 2021-11-11
AU2008338691A2 (en) 2011-03-10
US9951122B2 (en) 2018-04-24
ZA201004478B (en) 2011-12-28
NZ586611A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
BRPI0819971A2 (pt) anticorpos contra vírus influenza e métodos de seu uso
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
BRPI1014544A8 (pt) anticorpos anti-il-17f e metodos de uso dos mesmos
BR112012003064A2 (pt) anticorpos contra vírus sincicial respiratório (rsv) humano e métodos de uso
BRPI1012676A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI1011384A2 (pt) pro-proteinas e seus metodos de uso
BRPI0919531A2 (pt) anticorpos contra il17 humana e usos dos mesmos
BR112014012590A2 (pt) anticorpos anti-cd98 e métodos de uso dos mesmos
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0916269A2 (pt) dispositivo de modificação de tecido e seu método de uso
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
CO7020870A2 (es) Anticuerpos anti-htra1 y métodos de uso
BRPI1012000A2 (pt) "sistema combustores e métodos de uso dos mesmos"
BR112013014321A2 (pt) moduladores inovadores e métodos de uso
BRPI1015350A2 (pt) anticorpos de anti-ceacam1 e métodos de usar os mesmos
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
CO6862148A2 (es) Composiciones transdérmicas de ibuprofeno y métodos de uso de las mismas
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BR112012003232A2 (pt) "uso combinado de armadilhas gdf e eritropoietina ativadores receptor para aumentar níveis de glóbulos"
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0908175A2 (pt) derivados de polimixina e composição farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação
BR112014009837A2 (pt) uso eficaz da levedura e extrato de levedura

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]